Alps Advisors Inc. Takes Position in VBI Vaccines Inc. (NASDAQ:VBIV)

Alps Advisors Inc. bought a new stake in VBI Vaccines Inc. (NASDAQ:VBIVGet Rating) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 153,205 shares of the biopharmaceutical company’s stock, valued at approximately $124,000. Alps Advisors Inc. owned 0.06% of VBI Vaccines as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. State Street Corp lifted its stake in shares of VBI Vaccines by 31.1% in the 1st quarter. State Street Corp now owns 16,216,811 shares of the biopharmaceutical company’s stock valued at $26,920,000 after purchasing an additional 3,844,698 shares during the period. Cambridge Investment Research Advisors Inc. lifted its stake in shares of VBI Vaccines by 2.0% in the 2nd quarter. Cambridge Investment Research Advisors Inc. now owns 2,233,150 shares of the biopharmaceutical company’s stock valued at $1,806,000 after purchasing an additional 43,450 shares during the period. Charles Schwab Investment Management Inc. lifted its stake in shares of VBI Vaccines by 2.7% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 1,644,720 shares of the biopharmaceutical company’s stock valued at $2,731,000 after purchasing an additional 43,567 shares during the period. UBS Group AG increased its position in VBI Vaccines by 45.5% during the 1st quarter. UBS Group AG now owns 1,032,103 shares of the biopharmaceutical company’s stock valued at $1,714,000 after buying an additional 322,957 shares in the last quarter. Finally, Bank of America Corp DE increased its position in VBI Vaccines by 88.9% during the 1st quarter. Bank of America Corp DE now owns 809,425 shares of the biopharmaceutical company’s stock valued at $1,343,000 after buying an additional 380,839 shares in the last quarter. Hedge funds and other institutional investors own 39.96% of the company’s stock.

VBI Vaccines Price Performance

VBIV stock opened at $0.59 on Thursday. VBI Vaccines Inc. has a twelve month low of $0.55 and a twelve month high of $3.42. The company has a quick ratio of 2.61, a current ratio of 2.77 and a debt-to-equity ratio of 0.58. The firm has a market cap of $152.47 million, a PE ratio of -1.37 and a beta of 1.83. The business has a 50 day moving average of $0.68 and a 200 day moving average of $0.83.

Analysts Set New Price Targets

Separately, Raymond James lowered VBI Vaccines from a “strong-buy” rating to an “outperform” rating and reduced their price objective for the company from $5.00 to $2.00 in a research report on Friday, November 11th.

VBI Vaccines Profile

(Get Rating)

VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection.

Featured Stories

Institutional Ownership by Quarter for VBI Vaccines (NASDAQ:VBIV)

Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.